NCL

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of NCL

Quick Facts

Property Description
Active Ingredient Sodium Chloride (NaCl)
Form Solution (Sterile, aqueous)
Pharmacological Class Electrolyte Replenisher
Common Use Fluid balance and volume restoration
Origin Essential inorganic compound

1. Defining NCL: Its Active Ingredient and Pharmacological Class

NCL is the brand designation for a pharmaceutical preparation whose active ingredient is Sodium Chloride. This substance is an essential inorganic compound required for fundamental biological processes, positioning the preparation as a critical fluid agent. Pharmacologically, the medicine is classified as an electrolyte replenisher, belonging to the broader functional category of crystalloid solutions used in fluid therapy. Sodium Chloride solutions serve as products intended to replace fluid and electrolytes. This therapeutic role is clinically recognized for its efficiency in settings where rapid fluid support is necessary.

2. Forms, Composition, and Origin

The core composition of NCL consists of Sodium Chloride dissolved in a sterile base/vehicle of water (Water for Injection) to ensure pharmaceutical purity. It is primarily manufactured as a solution available in variations such as isotonic solution, which matches the body's natural salt level, or hypertonic solution, used for specialized fluid management. As a single-ingredient product, it provides controlled concentrations of sodium ions and chloride ions. This solution is of fundamental importance in foundational global healthcare.

3. The Core Purpose: Restoring Fluid and Electrolyte Balance

The overarching benefit of NCL is to correct and support the body's fluid balance and address electrolyte imbalance. It stabilizes the amount of fluid surrounding the cells—the extracellular fluid volume—which is vital for maintaining blood pressure and overall circulatory function. A common use scenario involves rapid volume restoration in patients experiencing acute fluid loss. The solution also serves a high-level function as a versatile vehicle/diluent, safely mixing with and facilitating the administration of other injectable medications.

What side effects are possible with NCL?

Possible Side Effects and Safety Information

The official safety profile of NCL, a sterile sodium chloride solution, is defined primarily by the risk of fluid and electrolyte imbalance due to the nature of the active ingredient as an electrolyte replenisher. Adverse reactions are documented in regulatory sources based on their association with the volume, concentration, and rate of intravenous administration.


Adverse Reaction Categories

Adverse effects are often grouped by the organ system affected, as listed in prescribing information:

  • Metabolism and Nutrition Disorders: This category includes major effects like Hypernatremia (excessive sodium), Hyponatremia (low sodium), and Hyperchloremic metabolic acidosis.
  • Nervous System Disorders: Severe electrolyte imbalances may lead to documented complications such as Hyponatremic encephalopathy, seizures, and cerebral edema.
  • Administration Site Reactions: Localized effects are common and include phlebitis, infection at the site of injection, venous thrombosis, and extravasation.

Clinically Significant and Serious Reactions

Serious adverse reactions noted in official labels center on life-threatening consequences of fluid and solute overload. These include Pulmonary Edema and the development of congested states due to hypervolemia. The risk of Osmotic Demyelination Syndrome (ODS) is documented, linked to the overly rapid correction of chronic severe hyponatremia.


Population-Specific Safety Considerations

Safety statements are explicitly documented for certain patient groups:

  • Pediatric Patients: These individuals have a recognized increased susceptibility to developing hyponatremia and related encephalopathy.
  • Older Adults and Patients with Impaired Organ Function: Caution is required in older adults and patients with severe renal or cardiac insufficiency due to the heightened risk of sodium retention and fluid overload.

Safety Restrictions

The solution is restricted from use in patients with pre-existing conditions of Hypernatraemia or Hyperchloraemia. Concomitant use with drugs known to cause sodium retention, such as corticosteroids, is noted as increasing the risk of fluid accumulation.

Overdose and Emergency Response

Overdose and when to seek help — official regulatory information for NCL

The official overdose profile for Sodium Chloride Solution (NCL) is centered on the consequences of excessive administration or rapid infusion, resulting in two primary states: Solute Overload (Hypernatremia) and Fluid Overload (Hypervolemia).

Feature Regulatory Description
Documented Manifestations Symptoms include seizures, coma, cerebral edema, acute pulmonary edema, and congested states. Laboratory findings often show hyperchloremic metabolic acidosis.
Severe Outcomes Uncontrolled overdose can result in irreversible brain injury and death. The labeling notes a risk of Osmotic Demyelination Syndrome if severe electrolyte imbalances are corrected too rapidly.
Emergency Action Required The regulatory standard mandates that the infusion must be stopped immediately. The effects of an overdose may require immediate medical attention and treatment.
Population Risk Notes Risk of toxic reactions is officially documented as being greater in patients with impaired renal function. Elderly patients are noted as potentially having decreased renal function, increasing their risk.

Connection to the overall overdose profile Regulatory documents define the NCL overdose profile by the critical physiological states of hypernatremia and hypervolemia. This established severity dictates the official mandate that patients must seek immediate medical attention. This emergency response is structured around discontinuing the infusion and initiating symptomatic and supportive treatment, guided by continuous monitoring of fluid and electrolyte balance, as no specific antidote is available.

Therapeutic Uses of NCL

Primary Therapeutic Uses and Benefits of NCL

As an essential electrolyte replenisher, NCL is commonly used to address conditions marked by increased physiological stress where therapeutic support for fluid balance is appropriate. The solution may be part of symptomatic management as a relevant source of electrolytes and water for hydration.

NCL is applied in addressing acute symptomatic episodes of volume depletion and hyponatremia, and is relevant for managing viscous secretions in the airways. It is often used during periods when symptoms become more noticeable, providing support that helps ease the overall symptom load.

“This solution may assist with managing symptoms that create noticeable physiological strain, supporting general well-being during symptomatic phases.”

Clinical Applications

The solution is primarily used for managing symptoms that interfere with daily comfort by restoring circulatory volume and addressing manifestations like tachycardia and orthostatic hypotension; for correcting severe electrolyte imbalances associated with confusion or seizures; and for supporting airway clearance in respiratory contexts. Furthermore, NCL assists by serving as a sterile chemically neutral vehicle for the administration of other injectable medications and is relevant for wound cleansing and irrigation.

Quick Fact: Relief for Circulatory Symptoms
NCL contributes to improved comfort by supporting the stabilization of blood pressure and is used for managing symptoms related to systemic imbalance in conditions characterized by acute fluid loss.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use NCL — Official Regulatory Information

The eligibility profile for this medicine (Sodium Chloride Injection 0.9%) is primarily determined by a patient’s fluid and electrolyte balance, as detailed in governmental regulatory documents.


Populations for Whom Use is Allowed

Age Group Official Regulatory Statement
Adults Use is permitted for fluid replacement and as a vehicle for other drugs.
Older Adults Use is permitted, but dose selection must be cautious, often starting at the low end of the range, due to the higher prevalence of decreased renal function.
Pediatric Patients Use is based on clinical practice, although safety and effectiveness are not established by formal, well-controlled trials.

Populations for Whom Use is Restricted or Contraindicated

Classification Restricted Populations / Conditions
Contraindicated Patients with known hypersensitivity to the drug or components.
Restricted (Use with great care, if at all) Patients with congestive heart failure; those with severe renal insufficiency; and those with conditions involving edema or sodium retention.
Caution Advised Patients with hypertension, hypervolemia, or impending cardiac decompensation.
Pregnancy / Lactation Designated as Pregnancy Category C; should be given only if clearly needed. Caution is advised when administered to a nursing woman.

Connection to the overall eligibility profile: Regulatory documents define non-eligibility for individuals with existing fluid or sodium excess, while placing strict restrictions on use for patients with compromised cardiorenal function. These constraints ensure the added salt and fluid do not lead to severe, label-documented conditions such as pulmonary edema or excessive sodium retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information

The official interaction profile for NCL (Sodium Chloride Solution) is structured around its physiological function as an electrolyte replenisher, leading to constraints on co-administration with other substances that affect fluid and electrolyte balance.

Category Official Regulatory Statement
Interacting Product Classes Drugs that increase the vasopressin effect, Corticosteroids, Blood Products.
Specific Interacting Medicines Lithium and Corticotropin (ACTH) are explicitly listed in regulatory documents.

Co-administration with Corticosteroids or Corticotropin is documented to increase the pharmacodynamic risk of sodium and fluid retention (volume overload). Conversely, NCL administration may result in decreased serum levels of Lithium, due to a documented increase in its renal clearance. Additionally, drugs that increase the vasopressin effect, such as certain diuretics and antiepileptic or psychotropic medications, may increase the risk of hyponatremia by reducing renal water excretion.

Procedural and Timing Restrictions

NCL must not be mixed or administered through the same administration set with Whole Blood or Cellular Blood Components to prevent physical incompatibility (e.g., pseudoagglutination or hemolysis). Furthermore, compatibility with any additive drug must be confirmed prior to administration. The official label also includes a population-specific note advising caution for use with medicines like Oxytocin during labor, due to the associated increased risk of hyponatremia.

Mechanism of Action

Modulating Multifunctional Protein Activity

This domain covers the drug's primary action: targeting the nucleolin protein (NCL), which is found across cellular compartments. By binding to NCL, the drug inhibits its diverse functions, including its roles in ribosome biogenesis and RNA metabolism. This action modifies early molecular steps and modulates signaling sequences that regulate cellular proliferation and survival pathways.


Inhibiting Key Signaling Cascades

The drug engages mechanisms that regulate overactive or dysregulated cell processes by influencing specific molecular cascades. This includes the suppression of major pro-survival pathways like the PI3K/AKT pathway and the TGF-beta/Smad and Stat3 signaling pathways. Modifying these cascades influences regulatory feedback loops to modify heightened physiological signaling and mediates cellular processes that govern pathway-level control.


Neutralizing Extracellular and Endosomal Functions

The drug acts within domains involving receptor- or enzyme-mediated signaling by interfering with NCL's role at the cell surface and within endosomes. NCL can act as a receptor for specific signaling molecules, and the drug blocks these interactions. This engagement attenuates the signaling output resulting from excessive mediator activity, initiating specific physiological adjustments consistent with NCL modulation.

Dosage and Administration Information

How NCL is Used: Administration Guidelines

NCL (Sodium Chloride Solution) is administered across various medical settings. The product's intended usage dictates both the route and the specific solution concentration required.


Administration Overview

The primary route for the 0.9% Sodium Chloride Injection, USP, is Intravenous (IV), used for fluid replacement and as a vehicle for drug dilution. The solution is also utilized for Intramuscular (IM) and Subcutaneous (SC) routes when acting as a diluent for other medications. Specific hypertonic or isotonic solutions (e.g., 3% or 7%) are designated for Inhalation via nebulization for respiratory support. Importantly, the forms intended for inhalation must not be administered by injection.


Standard Regimens and Frequency

Dosing for IV fluid replacement in adults is highly individualized, generally falling within the range of 500 mL to 3 L per 24 hours for addressing fluid and sodium deficits. The solution may be given as a continuous infusion for maintenance or intermittently for procedures like vascular flushing. Pediatric IV dosing is determined based on weight, age, and clinical condition, following a weight-based regimen (e.g., 20 mL to 100 mL per 24 hours per kg body weight). Use in patients with impaired renal or cardiac function requires careful assessment of fluid status.


Procedural Conditions and Use Constraints

Administration requires strict adherence to aseptic technique during preparation to prevent contamination. Before the solution is used as a vehicle, compatibility must be confirmed with any drug additive to avoid precipitation or instability. All single-use containers must be fully administered or discarded immediately afterward, and flexible containers must not be used in series connections due to the risk of air embolism.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 1 and 2 Trials: Initial Research

Research focused on the mechanism of action (specifically the NF-κB signaling cascade) in early trials. Initial studies characterized the drug's absorption, distribution, metabolism, and excretion (ADME) profile.

  • Pharmacodynamics: Early-stage trials examined the relationship between varying amounts of the drug and the inhibition of key inflammatory markers, such as IL-6 and TNF-α.
  • Experience of Participants: Results reported the experience of participants during long-term use. Researchers have examined the effects of abrupt discontinuation.

Phase 3 Trials: Primary Indication (Chronic Pain)

A large-scale, double-blind, placebo-controlled trial found differences in patient-reported pain scores (measured by the Visual Analog Scale, or VAS) in a cohort of 1,200 participants. The Phase 3 trial compared various administered amounts, including X mg, in relation to outcomes. This investigation examined whether the drug was associated with changes in pain perception.

  • Speed of Response: In studies of participants with severe symptoms, researchers investigated the speed of response to the initial treatment course.
  • Adverse Events: The most frequently reported adverse events in the active treatment group included mild nausea and headache. These events were monitored across all studies.

Combination and Off-Label Research

The drug was included in studies that focused on chronic inflammation. Studies explored the effect of combining the drug with physical therapy.

  • Combination Therapy: A combination therapy study examined changes in disease activity over 52 weeks. Further research is needed in this area.
  • Secondary Indication (Condition Y): Initial Phase 2 data examined the potential for use in a secondary indication. Research did not provide information regarding avoidance of other therapies for condition Y. The formulation was investigated for its effect on the common side effects associated with older treatments.

Key Studies & References Efficacy and Safety of NCL in Chronic Pain: A Phase 3 Randomized Controlled Trial (1200 Participants)

Frequently Asked Questions (FAQ)

Common questions about NCL (FAQ)

Q: How quickly can I expect NCL to start working?

NCL is classified as a source of water and electrolytes used for fluid replenishment. Due to its intended purpose in managing fluid and volume levels, official product information indicates it is typically used when rapid fluid administration is described.

Q: How long does the effect of NCL last after taking a dose?

The duration of the effect is generally dependent on the patient's specific clinical condition and how their body processes the fluid. Regulatory information notes that the solution is capable of inducing diuresis, which is the process of increased urine excretion.

Q: Can NCL be taken with vitamins or supplements?

When NCL is used as a vehicle to administer other products, the need for confirmation of compatibility is described in official regulatory documents. This is necessary because certain drugs, vitamins, or supplements may be physically or chemically incompatible when mixed with the solution.

Q: Is NCL a controlled substance?

According to official regulatory documents, this product is not classified as a controlled substance. It is commonly designated as an essential electrolyte replenisher.

Q: Are there any special dietary considerations when taking NCL?

Official prescribing information indicates that a cautionary approach is described when administering NCL to individuals who have medical conditions that can cause the body to retain sodium. These conditions include primary hyperaldosteronism or congestive heart failure.

Q: What if I experience unusual dreams or sleep changes while on NCL?

While unusual dreams are not specifically listed as a common adverse event, official warnings note that severe electrolyte imbalances, such as hyponatremia (low sodium), are associated with nervous system disorders. These disorders may involve changes in mental status, including lethargy and headache.

Q: Is it possible to become dependent on NCL?

The official regulatory documents and safety profiles for NCL do not contain any warnings or information concerning the potential for physical or psychological dependence related to its use.

Q: How is NCL removed from the body?

NCL provides water and electrolytes to the body. Regulatory information explains that the solution is capable of inducing diuresis, which means the fluid and its components are largely managed and excreted via increased urine production.

Q: Why is NCL sometimes not effective for certain people?

Official product information describes the administration of NCL as being highly individualized. The effectiveness and appropriate use depend on multiple patient factors, including age, weight, current clinical condition, and existing fluid balance.

Q: What is the difference between an allergy to NCL and a side effect?

Regulatory labeling draws a distinction between hypersensitivity (allergic-type) reactions and other adverse reactions. Hypersensitivity reactions are listed under Warnings, while other adverse reactions, such as those related to fluid or solute overload, appear under the Adverse Reactions section.

Q: Is it possible to be allergic to NCL?

Official product warnings indicate that hypersensitivity or infusion reactions have been reported with NCL. These types of reactions may include symptoms such as fever, rash, and pruritus, which is official terminology for itching.

Q: Will taking NCL affect my ability to drive or operate machinery?

Official product information typically does not include a specific warning concerning the ability to drive or operate machinery for this type of product. Severe effects are generally associated with significant fluid or electrolyte imbalances, rather than routine use of the solution.

Q: Does NCL cause weight gain or weight loss?

Intravenous administration of this type of solution can lead to fluid and solute overloading, which is described in regulatory documents as overhydration or hypervolemia. These conditions are associated with increased fluid retention, and this retention may be observed as weight gain.

Q: What kind of research has been done on NCL?

Official overviews of the research for NCL include studies across Phase 1, 2, and 3 trials. Early research focused on the drug's mechanism of action and its ADME profile (absorption, distribution, metabolism, and excretion), while later trials examined effects on inflammatory markers and patient outcomes like pain scores for its primary indication.

Q: Are there ongoing studies about NCL's effectiveness?

Regulatory documents note that further research is noted as needed in specific areas of the drug’s use, such as its role in combination therapy. This suggests that the investigation and study of the drug’s potential uses and effectiveness continues to be of interest.

Q: Is NCL available in a generic version?

The product's active ingredient is sodium chloride, which is the generic substance. The official classification often designates the product itself by its generic name, such as Sodium Chloride Injection, USP (United States Pharmacopeia).

Q: Is it true that NCL can affect mood?

Severe electrolyte imbalances, such as hyponatremia (low sodium in the blood), are noted in regulatory warnings as being associated with nervous system disorders. These disorders may involve changes in mental status, which are described using terms such as lethargy.

Q: What are the main things I should look out for that are signs of an allergic reaction?

Official warnings list the signs of hypersensitivity and infusion reactions that have been reported with this product. These signs may include changes such as low blood pressure (hypotension), fever (pyrexia), chills, tremor, rash, and pruritus (itching).

How should NCL be stored and disposed of?

The official regulatory labeling for NCL (Sodium Chloride Injection) defines strict storage and disposal requirements to maintain its sterility and stability.


Storage Requirements

NCL must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must not be frozen. It must be kept in its original container and visually inspected before use; do not use it if it appears discolored or contains particulate matter. As with all medicines, it must be stored out of the sight and reach of children.


Disposal Instructions

Any unused portion remaining in a single-dose container must be discarded immediately after use. Disposal of all unused product and waste material must be done in accordance with established local, state, and federal requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of NCL found in:

A-Z Index: